血管紧张素转换酶基因型与氢氯噻嗪长期降压疗效的关系  

Study on the correlation of angiotensin converting enzyme genotypes with the chronic antilitypertensive effects of hydrochlorthiazide

作　　者：孙丽霞[1] 浦践一[1] 沈扬[1] 

机构地区：[1]华北煤炭医学院附属医院,河北唐山063000

出　　处：《中国现代医学杂志》2010年第22期3406-3409,共4页China Journal of Modern Medicine

基　　金：河北省科技攻关项目(No:72761786)

摘　　要：目的探讨高血压病患者血管紧张素转换酶(ACE)基因不同基因型与氢氯噻嗪(HCTZ)长期降压疗效的关系。方法 232例高血压病患者同时服用HCTZ12.5mg,每日1次。于1年后测定血压结果。资料完整的220例患者按II、ID和DD3种基因型分组,比较不同基因型间的降压疗效。结果 II、ID和DD基因型患者1年后收缩压下降值分别为10.68mmHg(1mmHg=0.133kPa)、10.97mmHg和11.23mmHg,DD基因型患者收缩压下降值大于其他两型患者,但差异无显著性(P>0.05);3组间舒张压下降值,平均动脉压下降值差异无显著性。结论长期服用氢氯噻嗪,不同ACE基因型的高血压患者收缩压下降值无差异。【Objective】To study the correlation of angiotensin converting enzyme （ACE） genetypes with the chronic antihypertensive effects of hydrochlorthiazide （HCTZ） in hypertensive patients.【Methods】A total of 232 patients were on HCTZ 12.5 mg （once daily） for one year.220 patients with complete records were grouped into П,ID and DD genotypes,and antihypertensive effects were compared among different ACE genotypes.【Results】After 1 year treatment,the decreases in SBP of patients carrying DD,ID and DD were 10.68 mmHg,（1 mmHg=0.133 kPa）,10.97 mmHg and 11.23 mmHg ,the decrease in SBP of patients carrying DD was greater than that in other groups carrying II or ID,but there was no significant difference （P 0.05）.There was no significant difference in the decrease of DBP or MAP among these there groups.【Conclusion】Hypertensive patients carrying different ACE genotypes responded undifferently to HCTZ for a long time.

关 键 词：高血压 肽基二肽酶 基因型 治疗结果 

分 类 号：R544.1[医药卫生—心血管疾病]